全文获取类型
收费全文 | 5189篇 |
免费 | 229篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 53篇 |
儿科学 | 136篇 |
妇产科学 | 85篇 |
基础医学 | 688篇 |
口腔科学 | 47篇 |
临床医学 | 358篇 |
内科学 | 1406篇 |
皮肤病学 | 66篇 |
神经病学 | 638篇 |
特种医学 | 212篇 |
外科学 | 760篇 |
综合类 | 32篇 |
一般理论 | 1篇 |
预防医学 | 113篇 |
眼科学 | 47篇 |
药学 | 355篇 |
中国医学 | 3篇 |
肿瘤学 | 439篇 |
出版年
2023年 | 28篇 |
2022年 | 36篇 |
2021年 | 83篇 |
2020年 | 55篇 |
2019年 | 62篇 |
2018年 | 79篇 |
2017年 | 46篇 |
2016年 | 64篇 |
2015年 | 76篇 |
2014年 | 91篇 |
2013年 | 119篇 |
2012年 | 193篇 |
2011年 | 230篇 |
2010年 | 118篇 |
2009年 | 138篇 |
2008年 | 240篇 |
2007年 | 264篇 |
2006年 | 233篇 |
2005年 | 251篇 |
2004年 | 223篇 |
2003年 | 201篇 |
2002年 | 202篇 |
2001年 | 192篇 |
2000年 | 189篇 |
1999年 | 173篇 |
1998年 | 58篇 |
1997年 | 41篇 |
1996年 | 54篇 |
1994年 | 38篇 |
1993年 | 42篇 |
1992年 | 146篇 |
1991年 | 122篇 |
1990年 | 134篇 |
1989年 | 130篇 |
1988年 | 129篇 |
1987年 | 122篇 |
1986年 | 114篇 |
1985年 | 100篇 |
1984年 | 64篇 |
1983年 | 62篇 |
1982年 | 25篇 |
1981年 | 32篇 |
1979年 | 42篇 |
1977年 | 29篇 |
1972年 | 25篇 |
1970年 | 32篇 |
1969年 | 36篇 |
1968年 | 25篇 |
1967年 | 28篇 |
1966年 | 26篇 |
排序方式: 共有5439条查询结果,搜索用时 890 毫秒
991.
Matsuoka M 《Journal of Alzheimer's disease : JAD》2011,24(Z2):27-32
Despite a bulk of evidence supporting the idea that increased neurotoxic insults lead to Alzheimer's disease (AD), the possibility still remains that insufficiency of an endogenous defense system contributes to the disease progression. Humanin is a bioactive peptide that is likely to inhibit both neuronal death and dysfunction only related to AD by binding to a Humanin receptor on the cell-surface and by activating a STAT3-mediated signal, preventing the onset of dementia. A couple of recent studies presented evidence suggesting that the Humanin signal is decreased in neurons of AD patients. If this is the case, the restoration or activation of the Humanin signal in neurons may change the course of AD. 相似文献
992.
993.
Kazuhiko Matsuoka Tomomi Tamura Daisuke Tsuji Yukie Dohzono Keisuke Kitakaze Kazuki Ohno Seiji Saito Hitoshi Sakuraba Kohji Itoh 《Molecular therapy》2011,19(6):1017-1024
To develop a novel enzyme replacement therapy for neurodegenerative Tay-Sachs disease (TSD) and Sandhoff disease (SD), which are caused by deficiency of β-hexosaminidase (Hex) A, we designed a genetically engineered HEXB encoding the chimeric human β-subunit containing partial amino acid sequence of the α-subunit by structure-based homology modeling. We succeeded in producing the modified HexB by a Chinese hamster ovary (CHO) cell line stably expressing the chimeric HEXB, which can degrade artificial anionic substrates and GM2 ganglioside in vitro, and also retain the wild-type (WT) HexB-like thermostability in the presence of plasma. The modified HexB was efficiently incorporated via cation-independent mannose 6-phosphate receptor into fibroblasts derived from Tay-Sachs patients, and reduced the GM2 ganglioside accumulated in the cultured cells. Furthermore, intracerebroventricular administration of the modified HexB to Sandhoff mode mice restored the Hex activity in the brains, and reduced the GM2 ganglioside storage in the parenchyma. These results suggest that the intracerebroventricular enzyme replacement therapy involving the modified HexB should be more effective for Tay-Sachs and Sandhoff than that utilizing the HexA, especially as a low-antigenic enzyme replacement therapy for Tay-Sachs patients who have endogenous WT HexB. 相似文献
994.
Yamashita S Ueda A Hirahara T Kimura E Hirano T Uchino M 《Internal medicine (Tokyo, Japan)》2011,50(8):919-924
We report a patient with human T-cell lymphotropic virus type I (HTLV-I) infection, who presented with proximal extremity neurogenic muscular weakness followed by fulminant myelopathy, but with no upper motor symptoms. The symptoms were inconsistent with the World Health Organization or El Escorial criteria for HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) or amyotrophic lateral sclerosis (ALS). This case indicates that fulminant myelopathy without upper motor neuronal symptoms may occur long after the onset of HTLV-I-associated neurogenic proximal muscular weakness. Additionally, we report that treatment with high-dose steroid pulse therapy partially improves symptoms of lightning pain and sensory disturbance. 相似文献
995.
996.
997.
998.
Matsuoka H Ando K Ueshima K Babazono T Kario K Tanaka S Nakao K Fujita T;SAKURA Trial Investigators 《Clinical and experimental hypertension (New York, N.Y. : 1993)》2011,33(7):455-462
Recently, it has been demonstrated that L-/N-type calcium channel blockers (CCBs), cilnidipine, but not L-type CCB, decreased urinary protein in renin-angiotensin system (RAS), inhibitor-treated hypertensive patients with macroproteinuria. However, the antiproteinuric effect of cilnidipine was weaker in diabetic patients than in nondiabetic patients with macroproteinuria. This may be due to the fact that diabetic neuropathy was also developed in patients with advanced diabetic nephropathy because L-/N-type CCB has been considered to exert its renoprotetive effects through sympatholytic action. If so, the antiproteinuric effect of cilnidipine may be potent in patients with early stages of diabetic nephropathy. To elucidate our hypothesis, we designed a multi-center, open-labeled, randomized trial to compare the antialbuminuric effect between cilnidipine and amlodipine in RAS inhibitor-treated hypertensive (blood pressure [BP]: 130-180/80-110 mmHg) patients with type 2 diabetes and microalbuminuria (urinary albumin/creatinine [Cr] ratio: 30-300 mg/g). The primary study endpoint is the change in the urinary albumin/Cr ratio after a 1-year treatment. Enrollment began in April 2008 and was completed in March 2010. A total of 367 patients were randomly allocated to receive cilnidipine or amlodipine. At baseline, study subjects had 63.3± 8.5 years of age, 145.9 ± 12.2/80.8 ± 10.0 mmHg of BP, 101.0 ± 111.6 mg/g of urinary albumin/Cr. The trial is expected to show whether cilnidipine can exert an antialbuminuric effect in RAS inhibitor-treated hypertensive patients with early stages of diabetic nephropathy. 相似文献
999.
Ishimitsu T Ohno E Nakano N Furukata S Akashiba A Minami J Numabe A Matsuoka H 《Clinical and experimental hypertension (New York, N.Y. : 1993)》2011,33(6):366-372
We compared treatment with an angiotensin II receptor antagonist (ARB) and a calcium channel blocker (CCB) combination and a fixed-dose ARB and thiazide diuretic in 18 chronic kidney disease (CKD) patients. A randomized crossover study was performed using a fixed-dose combination of losartan-hydrochlorothiazide or losartan combined with controlled-release nifedipine. Both systolic blood pressure (SBP) and diastolic blood pressures (DBPs) were lower during the nifedipine period than during the diuretic period. No significant difference was observed in urinary albumin excretion, but the estimated glomerular filtration rate was higher in the nifedipine than in the diuretic period. Serum uric acid and low-density lipoprotein cholesterol were higher in the diuretic than in the nifedipine period. A significantly low cardio-ankle vascular index, an index of arterial wall stiffness, was observed in the nifedipine period. A combination of ARB and a controlled-release nifedipine at 20-40 mg used showed a superior antihypertensive effect in CKD patients compared to a fixed-dose combination of losartan 50 mg-hydrochlorothiazide 12.5 mg in terms of blood control. The former combination is considered advantageous for maintaining renal function and artery wall elasticity without influencing uric acid or lipid metabolism. 相似文献